ADD Medication Permanently Stunts Growth
Method: Naturalistic subgroups were established based on patterns of treatment with stimulant medication at baseline, 14-, 24-, and 36-month assessments: not medicated (n = 65), newly medicated (n = 88), consistently medicated (n = 70), and inconsistently medicated (n = 147). Analysis of variance was used to evaluate effects of subgroup and assessment time on measures of relative size (z scores) obtained from growth norms.
Results: The subgroup × assessment time interaction was significant for z height (p <.005) and z weight (p <.0001), due primarily to divergence of the newly medicated and the not medicated subgroups. These initially stimulant-naïve subgroups had z scores significantly >0 at baseline. The newly medicated subgroup showed decreases in relative size that reached asymptotes by the 36-month assessment, when this group showed average growth of 2.0 cm and 2.7 kg less than the not medicated subgroup, which showed slight increases in relative size.
Conclusions: Stimulant-naïve school-age children with Combined type attention-deficit/hyperactivity disorder were, as a group, larger than expected from norms before treatment but show stimulant-related decreases in growth rates after initiation of treatment, which appeared to reach asymptotes within 3 years without evidence of growth rebound.
VITIELLO, BENEDETTO; HECHTMAN, LILY; EPSTEIN, JEFFERY N.; PELHAM, WILLIAM E.; ABIKOFF, HOWARD B.; NEWCORN, JEFFREY H.; MOLINA, BROOKE S.G.; HINSHAW, STEPHEN P.; WELLS, KAREN C.; HOZA, BETSY; JENSEN, PETER S.; GIBBONS, ROBERT D.; HUR, KWAN; STEHLI, ANNAMARI
Effects of Stimulant Medication on Growth Rates Across 3 Years in the MTA Follow-up.
Journal of the American Academy of Child & Adolescent Psychiatry.